Trump Signs Executive Order to Accelerate Psychedelic Drug Research and Access

In Brief

The executive order is seen as a significant shift in federal policy, aiming to expand mental health treatment options and impact regulatory proces...

Key Facts

• President Trump signed an executive order to expedite research and regulatory review of psychedelic drugs for mental illness.
• The order follows a previous move in December 2025 to reclassify marijuana as a less dangerous drug.
• FDA Commissioner Dr. Marty Makary described the order as an 'historic moment' for psychedelic research.
• Psychedelic drug stocks rallied following news of the executive order.
• The order targets drugs such as psilocybin, MDMA, and ibogaine, and includes provisions for 'Right to Try' access.

What Happened

President Trump signed an executive order aimed at speeding up research, clinical trials, and regulatory review for psychedelic drugs used in mental health treatment. The move was described by FDA Commissioner Dr. Marty Makary as historic.

Why It Matters

This policy change could increase access to new mental health treatments, affect drug development timelines, and influence broader drug reform debates. The order has already impacted financial markets and may shape future regulatory decisions.

What's Next

Observers are watching for FDA implementation details, potential expansion of clinical trials, and further legislative or regulatory actions related to psychedelics and cannabis reform.